Table 2.
Clinical-epidemiological features of our validation series of 561 patients
| Clinical characteristics | |
|---|---|
| Follow-up, mo | |
| Mean (SD) | 56.5 (27.7) |
| Median (min–max) | 50 (3–146) |
| Age, yy | |
| Mean (SD) | 71.9 (5.7) |
| Median (min–max) | 73 (51–88) |
| PSA, ng/mL | |
| Mean (SD) | 12.93 (30.96) |
| Median (min–max) | 7.70 (1.14–680) |
| T staging, no (%) | |
| cT1 | 355 (63%) |
| cT2 | 182 (33%) |
| cT3-4 | 24 (4%) |
| bGS, no (%) | |
| ≤ 6 | 220 (39%) |
| 3 + 4 | 174 (31%) |
| 4 + 3 | 69 (12%) |
| 8 | 55 (10%) |
| 9–10 | 43 (8%) |
| Biopsy cores sampled, no | |
| Mean (SD) | 11.0 (4.6) |
| Median (min–max) | 10 (2–35) |
| %PC, % | |
| Mean (SD) | 41.3% (27.8) |
| Median (min–max) | 38% (4–100) |
| N staging, % | |
| Not performed | 72% |
| performed N0 | 27.3% |
| performed N1 | 0.7% |
| M staging, % | |
| Not performed | 74% |
| performed M0 | 26% |
| D’Amico risk class, no (%) | |
| Low | 119 (21%) |
| Intermediate | 223 (40%) |
| High | 219 (39%) |
| Candiolo risk class, no (%) | |
| Very-low | 133 (24%) |
| Low | 211 (37%) |
| Intermediate | 133 (24%) |
| High | 56 (10%) |
| Very-high | 28 (5%) |
| RT dose to prostate-CTV, ED2Gy, α/β = 2,5 | |
| Mean (SD) | 77.7 (2.4) |
| Median (min–max) | 78 (72–82) |
| Fractionation schedule, % | |
| Std fractionation 2 Gy /fr | 77% |
| Hypo-fractionation 2,7 Gy /fr | 23% |
| RT technique, % | |
| 3DCRT | 77% |
| IMRT-IGRT | 23% |
| Seminal vesicles irradiation, % | |
| No | 22% |
| Yes | 78% |
| Pelvic nodal irradiation, % | |
| No | 98% |
| Yes | 2% |
| Exclusive RT | 24% |
| RT + ADT | 76% |
| ADT duration, mo | |
| Mean (SD) | 13.0 (10.1) |
| Median (min–max) | 8 (1–46) |
| ADT drug, % | |
| Anti-Androgen | 37% |
| LHRH-analogue | 49% |
| TAB | 14% |
SD, standard deviation; ED2Gy, equivalent dose at standard dose of 2 Gy per fraction; RT, radiotherapy; ADT, androgen deprivation therapy